CN116829137A - 用于治疗阿尔茨海默氏病的作为多靶标治疗剂的萘衍生物的药物组合物 - Google Patents
用于治疗阿尔茨海默氏病的作为多靶标治疗剂的萘衍生物的药物组合物 Download PDFInfo
- Publication number
- CN116829137A CN116829137A CN202180091389.3A CN202180091389A CN116829137A CN 116829137 A CN116829137 A CN 116829137A CN 202180091389 A CN202180091389 A CN 202180091389A CN 116829137 A CN116829137 A CN 116829137A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- alzheimer
- treatment
- compounds
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000087A CU24720B1 (es) | 2020-11-24 | 2020-11-24 | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
| CU2020-0087 | 2020-11-24 | ||
| PCT/CU2021/050012 WO2022111742A1 (es) | 2020-11-24 | 2021-11-18 | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116829137A true CN116829137A (zh) | 2023-09-29 |
Family
ID=80034851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180091389.3A Pending CN116829137A (zh) | 2020-11-24 | 2021-11-18 | 用于治疗阿尔茨海默氏病的作为多靶标治疗剂的萘衍生物的药物组合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299334A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4252749A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023551249A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230118112A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116829137A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021388673A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200071A1 (cg-RX-API-DMAC7.html) |
| CU (1) | CU24720B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006072A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022111742A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119523898A (zh) * | 2024-12-02 | 2025-02-28 | 肇庆学院 | 多靶点药物的经鼻给药制剂及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106691A1 (en) * | 2013-02-28 | 2016-04-21 | Centro De Neurociencias De Cuba (Neuronic) | Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases |
| WO2020094161A1 (es) * | 2018-11-06 | 2020-05-14 | Centro De Neurociencias De Cuba | Nanopartículas de óxidos metálicos conjugados con derivados de naftaleno en cuanto agentes de contraste para la detección de placas beta amiloides por imágenes de resonancia magnética |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| US20040254146A1 (en) | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| CN1621039A (zh) | 2003-11-25 | 2005-06-01 | 上海医药工业研究院 | 石杉碱甲及其衍生物或其盐的经鼻脑靶向制剂 |
| EP1715843A1 (en) | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| WO2006009769A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| WO2007002497A1 (en) | 2005-06-23 | 2007-01-04 | Envivo Pharmaceuticals, Inc. | Method of treating neurological disorders using clotrimazole and derivatives thereof |
| US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
| US7745670B2 (en) * | 2008-06-27 | 2010-06-29 | Codman & Shurtleff, Inc. | Curcumin-Resveratrol hybrid molecule |
| CU23844B1 (es) | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer |
-
2020
- 2020-11-24 CU CU2020000087A patent/CU24720B1/es unknown
-
2021
- 2021-11-18 MX MX2023006072A patent/MX2023006072A/es unknown
- 2021-11-18 CN CN202180091389.3A patent/CN116829137A/zh active Pending
- 2021-11-18 AU AU2021388673A patent/AU2021388673A1/en not_active Abandoned
- 2021-11-18 US US18/038,494 patent/US20240299334A1/en active Pending
- 2021-11-18 CA CA3200071A patent/CA3200071A1/en active Pending
- 2021-11-18 KR KR1020237020732A patent/KR20230118112A/ko active Pending
- 2021-11-18 WO PCT/CU2021/050012 patent/WO2022111742A1/es not_active Ceased
- 2021-11-18 EP EP21848149.7A patent/EP4252749A1/en active Pending
- 2021-11-18 JP JP2023531700A patent/JP2023551249A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106691A1 (en) * | 2013-02-28 | 2016-04-21 | Centro De Neurociencias De Cuba (Neuronic) | Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases |
| WO2020094161A1 (es) * | 2018-11-06 | 2020-05-14 | Centro De Neurociencias De Cuba | Nanopartículas de óxidos metálicos conjugados con derivados de naftaleno en cuanto agentes de contraste para la detección de placas beta amiloides por imágenes de resonancia magnética |
Non-Patent Citations (3)
| Title |
|---|
| SUCHITIL RIVERA-MARRERO 等: "A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer\'s disease", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 28, no. 20, 15 October 2020 (2020-10-15), pages 115700 * |
| 常忆凌: "药剂学", 31 May 2008, 中国医药科技出版社, pages: 291 - 295 * |
| 张洋 等: "聚合物制备工程", 31 January 2001, 中国轻工业出版社, pages: 159 - 161 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023551249A (ja) | 2023-12-07 |
| KR20230118112A (ko) | 2023-08-10 |
| EP4252749A1 (en) | 2023-10-04 |
| AU2021388673A1 (en) | 2024-03-28 |
| US20240299334A1 (en) | 2024-09-12 |
| WO2022111742A1 (es) | 2022-06-02 |
| CU20200087A7 (es) | 2022-07-08 |
| WO2022111742A4 (es) | 2022-11-03 |
| CA3200071A1 (en) | 2022-06-02 |
| MX2023006072A (es) | 2023-06-29 |
| CU24720B1 (es) | 2024-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210308120A1 (en) | Use of Amitriptyline for Blocking Brain Hemichannels and Method for Potentiating its Effect in Vivo | |
| RU2493868C2 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ | |
| US20250228833A1 (en) | Methods and compositions for treating agitation | |
| CN107921029B (zh) | 采用lsd1抑制剂治疗多发性硬化的方法 | |
| CN101442990A (zh) | 消旋卡多曲的新型给药形式 | |
| KR20190083369A (ko) | 약물 전달 시스템 | |
| AU3409097A (en) | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction | |
| KR20150139830A (ko) | 신경변성 및 기타 질환의 치료를 위한 조성물 및 방법 | |
| US5441933A (en) | Pharmaceutical compositions and dosage forms for the oral administration of calcitonin | |
| CN1173701C (zh) | 含有米氮平的口内崩解组合物 | |
| JP2008526953A (ja) | 炎症性疾患のプラジカンテルでの治療 | |
| EP4252749A1 (en) | Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease | |
| JP2026069500A (ja) | 線維症を治療するためのシクロスポリン類似体の使用 | |
| CN118557536A (zh) | 一种卢美哌隆口崩片组合物及其制备方法和应用 | |
| HK40092074A (en) | Pharmaceutical composition of naphthalene derivatives as multi-target therapeutic agents for the treatment of alzheimer's disease | |
| AU2012241189A1 (en) | Fast Dissolving Solid Dosage Form | |
| JP2014528395A (ja) | 口腔内分散性製剤 | |
| CN101675932B (zh) | 一种防治肌萎缩侧索硬化的组合物 | |
| US20250009698A1 (en) | Nervonic acid-based compositions and methods | |
| US20240009148A1 (en) | Cystamine Formulations and Uses Thereof | |
| WO2025128666A1 (en) | Combination of latrepirdine and a pharmacokinetic stabilizer | |
| WO2024246686A1 (en) | Treatment for amyotrophic lateral sclerosis (als) | |
| JP2025529123A (ja) | 急性ストレス障害を処置するための方法及び組成物 | |
| CN119156207A (zh) | 用于治疗肌萎缩性侧索硬化的方法和组合物 | |
| CA2258662C (en) | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40092074 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |